IoT Development Company in Boston

Endpoint count and regulatory regime are the two axes on Boston connected-device work. Programmes run as a scoped Boston IoT pilot over twelve to twenty-two weeks for a single-asset proof of value (connected infusion pump prototype, single-bioreactor cleanroom monitor, single-robot telemetry stack) covering firmware or edge gateway, ingestion, dashboard, and the regulatory scoping documentation, a multi-site hospital RTLS or smart-bed deployment at Mass General Brigham, Boston Children's, or Beth Israel scale (500 to 5,000 endpoints) including FDA 524B SBOM and disclosure infrastructure, HIPAA audit logging, and integration with the hospital's Epic or Meditech instance, a biotech cleanroom and cold-chain deployment at Moderna, Vertex, Biogen, or Sanofi Cambridge scale including 21 CFR Part 11 audit trails and IQ/OQ/PQ documentation, or defence and robotics platform telemetry at iRobot, Boston Dynamics, Raytheon, or Draper scale, scaled by ITAR scope. USD, fixed-fee, no T&M sprawl.

Section 524B of the Federal Food, Drug, and Cosmetic Act (added by the Consolidated Appropriations Act, 2023) requires manufacturers of cyber devices to submit, as part of premarket submission, a plan to monitor, identify, and address postmarket cybersecurity vulnerabilities, design and maintain processes to provide reasonable assurance that the device and related systems are cybersecure, provide an SBOM (software bill of materials), and comply with such other requirements as FDA may require. The FDA September 2023 final guidance on cybersecurity in medical devices operationalises this with SBOM in SPDX or CycloneDX, a coordinated vulnerability disclosure surface, a documented patch SLA, and threat modelling at premarket. Our connected medical device builds (infusion pumps, monitors, imaging modalities, surgical robots, wearables) ship with all five artifacts cut on every build, ready for the 510(k) or De Novo cybersecurity section. Mass General Brigham and Boston Children's clinical engineering will not deploy a device without these on the shelf today, regardless of submission date.

201 CMR 17.00 (Standards for the Protection of Personal Information of Residents of the Commonwealth) requires any person or entity that owns or licenses personal information about a Massachusetts resident to develop, implement, and maintain a comprehensive written information security program (WISP) covering administrative, physical, and technical safeguards. For IoT systems that collect Massachusetts resident PII (driver identifiers in fleet telematics, patient identifiers in remote monitoring, employee identifiers in access control) the WISP must include risk assessment, access controls, encryption of PII transmitted across public networks or stored on portable devices, monitoring, secure user authentication, secure access controls including unique IDs and reasonably secure passwords, and incident response. Massachusetts Chapter 93H (breach notification) requires notice to the Attorney General, the Director of Consumer Affairs and Business Regulation, and affected residents as soon as practicable and without unreasonable delay. We design IoT systems to satisfy both standards by default.

Yes. Moderna, Vertex Pharmaceuticals, Biogen, Sanofi Cambridge, Pfizer Cambridge, and Takeda run connected cleanroom environmental monitors (temperature, humidity, differential pressure, particle count), bioreactor PAT sensors (pH, DO, OD, capacitance), and cold-chain trackers (Sensitech, Berlinger, Tive, ELPRO, Roambee class hardware) under 21 CFR Part 11 (electronic records and signatures), EU GMP Annex 11, and the FDA September 2022 draft guidance on Computer Software Assurance for Production and Quality System Software. Our builds deliver immutable audit trails (typically append-only ledgers in DynamoDB or PostgreSQL with cryptographic hash chaining), role-based electronic signature surfaces, IQ/OQ/PQ documentation, and a Computer System Validation (CSV) pack the sponsor's QA can present to a regulator. We coordinate with the client's GxP team and their validation consultant; we do not pretend to be the validation consultant of record.

Yes, within scope. iRobot (Bedford, consumer floor-care robotics), Boston Dynamics (Waltham, Atlas and Spot platforms now Hyundai-owned), Raytheon Technologies (Waltham defense), MITRE (Bedford FFRDC), Draper Laboratory (Cambridge), and Lincoln Laboratory (MIT-operated FFRDC in Lexington) operate platform telemetry, autonomy sensor fusion, fleet management, and field test harnesses. Commercial and dual-use work routes through our standard delivery hubs. Classified or export-controlled work under ITAR (22 CFR 120-130) or EAR (15 CFR 730-774) routes through US person staffing on US soil and we say so plainly during scoping, including any restrictions on Edmonton or Chandigarh hub involvement. Most platform telemetry, sim-to-real pipelines, and fleet ops dashboards are unclassified and route normally.

Mass General Brigham, Boston Children's Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Brigham and Women's Hospital all run mature vendor security review programs (typically a HITRUST CSF or NIST 800-66 Rev 2 questionnaire, a HIPAA Security Rule walkthrough, an SOC 2 Type II report request, and a clinical engineering medical device security review under MDS2 form). Our engagement pack includes a populated MDS2 (Manufacturer Disclosure Statement for Medical Device Security), a draft Business Associate Agreement aligned with their template, an SBOM, a vulnerability disclosure surface, a documented patch SLA, and an incident response runbook tied to Chapter 93H timelines. We build to the intake requirements MGB, Boston Children's, and Beth Israel publish, and we keep that pack updated against each system's current form.

A connected medical device prototype with FDA 524B-ready artifacts (firmware with secure boot and signed OTA, SBOM, vulnerability disclosure surface, patch SLA, threat model, premarket cybersecurity documentation pack) takes eighteen to twenty-eight weeks. Hospital RTLS or smart-bed rollouts at Mass General Brigham, Boston Children's, or Beth Israel scale (500 to 5,000 endpoints) take twenty-eight to forty-four weeks. Biotech cleanroom and cold-chain deployments at Moderna, Vertex, Biogen, or Sanofi Cambridge with 21 CFR Part 11 audit trails and IQ/OQ/PQ documentation take twenty-two to thirty-six weeks. Defense and robotics platform telemetry (iRobot, Boston Dynamics, Raytheon, Draper) takes twenty to thirty-two weeks. Financial services trading-floor environmental and access IoT at Fidelity, State Street, or BNY Mellon Boston takes sixteen to twenty-six weeks. Fixed-fee.

Massachusetts charges a 5% flat individual income tax (with a 4% surtax on income over $1M under the 2022 Fair Share Amendment, total 9% at the top) and an 8% corporate excise on income plus a 0.26% net worth measure. Massachusetts sales tax is 6.25% statewide, and personal services (software design and engineering labor) are generally not subject to sales tax, while prewritten software (canned software) and SaaS in certain configurations can be. The 2021 Massachusetts technical information release TIR 21-7 clarified that prewritten software is taxable whether sold electronically or otherwise. We invoice in USD, accept ACH and wire, provide W-9 documentation, route hardware sales through US delivery entities to handle Massachusetts sales tax cleanly, and route international clients through Canadian or Indian entities under treaty. Hospital and biotech 501(c)(3) clients (Mass General Brigham, Boston Children's, Dana-Farber, Whitehead Institute) get standard nonprofit billing treatment with appropriate exemption certificates.